Retatrutide Shows Major Weight Loss, Knee Pain Relief

Two Phase 3 trials of Eli Lilly's experimental drug produced large weight reductions and relief from knee osteoarthritis pain in more than 1,000 adults.

Updated on Nov. 8, 2026 in Weight Loss

Retatrutide Shows Major Weight Loss, Knee Pain Relief

Live Poll

Would you consider a weight-loss drug if it could also ease your joint pain?

Two Phase 3 clinical trials involving more than 1,000 adults found that Eli Lilly's experimental drug retatrutide produced major weight loss and reduced knee osteoarthritis pain. The drug is being considered for FDA approval for both weight loss and knee osteoarthritis relief.

Why it matters

Weight loss reduces load on the knees, which lessens pain and improves function, so the trial results point to a possible treatment benefit beyond weight alone. If approved, retatrutide could become the next GLP-1-class weight-loss option on the U.S. market.

The Phase 3 trials produced up to 25% average body-weight loss on high doses, with about two-thirds of active-group participants reporting at least a 50% knee pain reduction compared with a 38% reduction in the placebo group. The source does not report the trial duration or whether these effects will persist after treatment ends.

The players

Eli Lilly

Eli Lilly is a major American pharmaceutical company that developed the experimental drug retatrutide.

Northwestern University

Northwestern University is a private research university in Illinois that led the two Phase 3 trials of retatrutide.

The details

Retatrutide is a triple-hormone receptor agonist administered as a once-weekly injection that activates three natural hormone receptors. Some study participants lost up to a hundred pounds or more, and the drug also produced reduced blood pressure and inflammation as secondary effects.

November 8, 2026: Article published on the trial results for retatrutide.

Health Landscape

Retatrutide extends the GLP-1 drug class, which previously relied on semaglutide and tirzepatide, by activating three hormone receptors instead of one or two. The trial results show a higher percentage of weight loss than those existing single- and dual-receptor drugs produced in their respective studies.

If approved, retatrutide would add a once-weekly injection option for adults seeking weight loss or knee osteoarthritis pain relief. Patients should discuss any new treatment with a physician, as the drug is not yet approved beyond compassionate use.

The takeaway

Retatrutide's trial results suggest that losing substantial body weight may also ease joint pain for people with knee osteoarthritis. Readers considering weight-loss treatments should consult a healthcare provider about options that fit their own health needs.